Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-Compromise Study of high-titer anti-SARS-CoV-2 immunoglobulin in hospitalized immunocompromised adults with COVID-19
NL-OMON51203Phase 2Suspended
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Nanogam Plus in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Severe course of disease by day 28. Started Apr 2021; status: suspended.
02
Drugs
Nanogam Plus
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51203.